natgillin/translations-raw huggingface dataset:
It is generally recommended that patients start treatment with 63 micrograms at dose 1 (on day 0), increasing to 94 micrograms at dose 2 (on day 14), reaching the full dose of 125 micrograms by dose 3 (on day 28) and continuing with the full dose (125 micrograms) every 2 weeks (14 days) thereafter (see Table 1). 
Općenito se preporučuje da bolesnik započinje liječenje s 1. dozom od 63 mikrograma (0. dan), zatim je poveća u 2. dozi na 94 mikrograma (14. dan), dosegnuvši 3. dozu kao punu dozu od
5.3 Preclinical safety data 
5.3 Neklinički podaci o sigurnosti primjene Toksičnost
In the ATTAIN extension study, long-term efficacy with Plegridy was maintained with continuous treatment up to 4 years as shown by clinical and MRI measures of MS disease activity. 
U nastavku ispitivanja ATTAIN, klinička i MR mjerenja aktivnosti multiple skleroze pokazala su da se dugoročna djelotvornost Plegridyja održala uz kontinuirano liječenje do 4 godine.
Sodium acetate trihydrate Acetic acid, glacial Arginine hydrochloride Polysorbate 20 
FARMACEUTSKI PODACI 6.1 Popis pomoćnih tvari natrijev acetat trihidrat acetatna kiselina, ledena argininklorid polisorbat 20
What Plegridy is used for 
Za što se koristi Plegridy
The ADRs are presented as MedDRA preferred terms under the MedDRA System Organ Class. 
Nuspojave su navedene prema MedDRA-inim preporučenim pojmovima i razvrstane po MedDRA klasifikaciji organskih sustava.
Pulmonary arterial hypertension┼ 
plućna arterijska hipertenzija┼ nepoznato
Fertility and developmental studies in rhesus monkeys have been carried out with non-pegylated interferon beta-1a. 
Ispitivanja plodnosti i razvoja u rezus majmuna provedena su s nepegilirarnim interferonom beta-1a.
Flu-like symptoms are more common when you first start using Plegridy. 
Simptomi nalik gripi češći su na početku liječenja Plegridyjem.
- If you have trouble handling the syringe, ask your doctor or nurse who may be able to help. 
Ako imate problema pri rukovanju štrcaljkom, zatražite od svog liječnika ili medicinske sestre da Vam pomogne.
Solution for injection 2 pre-filled pens 
Otopina za injekciju 2 napunjene brizgalice
Plegridy 63 micrograms solution for injection in pre-filled syringe Plegridy 94 micrograms solution for injection in pre-filled syringe Plegridy 125 micrograms solution for injection in pre-filled syringe Plegridy 63 micrograms solution for injection in pre-filled pen Plegridy 94 micrograms solution for injection in pre-filled pen Plegridy 125 micrograms solution for injection in pre-filled pen 
Plegridy 63 mikrograma otopina za injekciju u napunjenoj štrcaljki Plegridy 94 mikrograma otopina za injekciju u napunjenoj štrcaljki Plegridy 125 mikrograma otopina za injekciju u napunjenoj štrcaljki Plegridy 63 mikrograma otopina za injekciju u napunjenoj brizgalici Plegridy 94 mikrograma otopina za injekciju u napunjenoj brizgalici Plegridy 125 mikrograma otopina za injekciju u napunjenoj brizgalici
1 pre-filled syringe of 63 micrograms 1 pre-filled syringe of 94 micrograms 
1 napunjena brizgalica od 63 mikrograma 1 napunjena brizgalica od 94 mikrograma
Quickly insert the needle straight into the skin fold until the needle is fully under the skin. 
Brzim potezom ubodite iglu ravno u nabor kože tako da igla cijela uđe pod kožu (pogledajte sliku H).
(uncommon - may affect up to 1 in 100 people) If you get any of these: 
- Ozbiljne alergijske reakcije (manje često - mogu se pojaviti u manje od 1 na 100 osoba) Ako vam se pojavi bilo što od sljedećeg:
Cases of nephrotic syndrome with different underlying nephropathies including collapsing focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), membranoproliferative glomerulonephritis (MPGN) and membranous glomerulopathy (MGN) have been reported during treatment with interferon-beta products. 
Slučajevi nefrotskog sindroma s različitim nefropatijama u podlozi, uključujući kolapsnu fokalnu segmentalnu glomerulosklerozu (FSGS), bolest minimalnih promjena (engl. minimal change disease,
Grey 
Siva
Plegridy pre-filled syringe must not be used if the liquid is coloured, cloudy, or contains floating particles. 
Plegridy u napunjenoj štrcaljki ne smije se koristiti ako je tekućina obojena, zamućena ili ako sadrži plutajuće čestice.
If you get any of these symptoms: - Any break in the skin together with swelling, inflammation or fluid leaking around the injection site 
- bilo kakvo oštećenje kože popraćeno oteklinom, upalom ili curenjem tekućine oko mjesta injekcije
- Feeling off-balance or light headed, walking problems, stiffness and muscle spasms, tiredness, 
Simptomi mogu uključiti: - osjećaj neravnoteže ili ošamućenosti, probleme s hodanjem, ukočenost i grčeve mišića, umor,
Do not pull back on the plunger. 
Nemojte vraćati kapicu na brizgalicu.
Pack sizes: - The Plegridy Initiation Pack contains one orange pre-filled syringe of 63 micrograms and one blue pre-filled syringe of 94 micrograms. 
Veličine pakiranja: - Plegridy pakiranje za početak liječenja sadrži jednu narančastu napunjenu brizgalicu od 63 mikrograma i jednu plavu napunjenu brizgalicu od 94 mikrograma.
Dose 1 
1. doza
The majority of enzyme elevations were <3 times the upper limit of normal (ULN). 
Većina povišenih razina enzima su bile <3 puta gornje granice normale (GGN) Povišenje alanin aminotransferaze i aspartat aminotransferaze (>5 puta GGN), zabilježeno je u 1% i u
Plegridy pre-filled pen must not be used if the liquid is coloured, cloudy, or contains floating particles. 
Plegridy u napunjenoj brizgalici ne smije se koristiti ako je tekućina obojena, zamućena ili ako sadrži plutajuće čestice.
• Plegridy pre-filled syringe is for subcutaneous injection (injection into skin). 
• Napunjena štrcaljka Plegridyja namijenjena je za davanje potkožne injekcije (supkutane injekcije).
Treatment with Plegridy should not be restarted (see section 
Terapiju Plegridyjem ne smije se ponovno započeti (vidjeti dio 4.8).
Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome* 
Poremećaji krvi i limfnog sustava tromobocitopenija manje često trombotička mikroangiopatija uključujući trombotičku trombocitopeničnu purpuru/hemolitičko-uremijski sindrom*
When you are ready to inject, carefully follow the instructions in section 7 “Instructions for injecting Plegridy pre-filled syringe”, at the end of this leaflet. 
Kada ste spremni za ubrizgavanje, pažljivo slijedite upute u dijelu 7 “Upute za ubrizgavanje Plegridyja u napunjenoj štrcaljki”, na kraju ove upute o lijeku.
Events were reported at various time points during treatment and may occur several weeks to several years after starting treatment with interferon beta. 
Događaji su zabilježeni u različitim vremenima tijekom liječenja, a mogu se pojaviti nekoliko tjedana do nekoliko godina nakon početka liječenja interferonom beta.
In post marketing experience, serious hypersensitivity events including cases of anaphylaxis (frequency not known) have been reported following Plegridy administration. 
U razdoblju nakon stavljanja lijeka u promet zabilježeni su ozbiljni slučajevi preosjetljivosti nakon primjene Plegridyja, uključujući anafilaksiju (nepoznate učestalosti).
Initiation Pack. 
iz pakiranja.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Pre-Filled Syringe Double Lid 125 mcg 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP Pakiranje s napunjenom štrcaljkom od 125 μg i dvostrukim poklopcem
Whether to discontinue therapy following a single site of necrosis is dependent on the extent of necrosis (see section 4.8). 
ovisi o opsegu nekroze (vidjeti dio 4.8).
Table on the inner lid Injection Record Day 0 (63 micrograms) Day 14 (94 micrograms) Date 
0. dan (63 mikrograma) 14. dan (94 mikrograma) Datum
P-value p≤0.0001 
P-vrijednost p≤0,0001
It is not known whether peginferferon beta-1a is secreted in human milk. 
Nije poznato izlučuje li se peginterferon beta-1a u majčino mlijeko.
- If you have trouble handling the pen, ask your doctor or nurse who may be able to help. 
Ako imate problema pri rukovanju brizgalicom, zatražite od svog liječnika ili medicinske sestre da Vam pomogne.
Peginterferon beta-1a has not been tested for carcinogenicity in animals. 
Kancerogeneza Kancerogenost peginterferona beta-1a nije ispitana u životinja.
┼ Class label for interferon products, see below Pulmonary arterial hypertension $ Class label for interferon products 
┼ Značajka skupine lijekova koji sadrže interferon, vidjeti u nastavku Plućna arterijska hipertenzija.
• For the first injections, you can use the record table printed on the inside of the lid of the 
• Za prve injekcije možete koristiti tablicu za bilježenje koja je otisnuta na unutarnjem dijelu poklopca pakiranja za početak liječenja.
(common - may affect up to 1 in 10 people) If you: Feel unusually sad, anxious or worthless or Have thoughts about suicide 
Ako se: - osjećate neuobičajeno tužno, tjeskobno ili bezvrijedno ili
When you are ready to inject, carefully follow the instructions in section 7 “Instructions for injecting Plegridy pre-filled pen”, at the end of this leaflet. 
Kada ste spremni za ubrizgavanje, pažljivo slijedite upute u dijelu 7 „Upute za ubrizgavanje Plegridyja u napunjenoj brizgalici“, na kraju ove upute o lijeku.
- You will need blood tests to determine your numbers of blood cells, blood chemistry and your levels of liver enzymes. 
Ostalo što treba uzeti u obzir kada se primjenjuje Plegridy Trebat ćete obaviti krvne pretrage kako bi se utvrdio broj krvnih stanica, krvna slika i razina Vaših jetrenih enzima.
Step 6: Give the injection a. Hold the pen over your injection site. 
6. korak: Dajte injekciju a.
These blood tests will be in addition to the tests which are normally done to monitor your MS. - The functioning of your thyroid gland will be checked regularly or whenever thought necessary by your doctor for other reasons. 
Redovito će se provjeravati funkcioniranje Vaše štitne žlijezde ili u bilo kojem trenutku kada Vaš liječnik to procijeni potrebnim.
Slight decreases in mean red blood cell (RBC) counts were observed in Plegridy treated patients. 
Blagi pad srednje vrijednosti broja crvenih krvnih stanica uočen je u bolesnika liječenih Plegridyjem.
Plegridy 125 mcg injection peginterferon beta-1a SC 
Plegridy 125 μg injekcija peginterferon beta-1a s.c.
The mean steady state clearance of peginterferon beta-1a was 4.1 ± 0.4 L/hr. 
Srednja vrijednost klirensa peginterferona beta-1a u stanju dinamičke ravnoteže iznosila je 4,1 ± 0,4 l/h.
No information is available on the potential effects of peginterferon beta-1a on male fertility. 
Nema dostupnih podataka o potencijalnim učincima peginterferona beta-1a na mušku plodnost.
• Before you use the pen for the first time, your doctor or nurse should show you or your carer how to prepare and inject the pen. 
• Prije nego što prvi put upotrijebite brizgalicu, liječnik ili medicinska sestra moraju Vama ili
(rare - may affect up to 1 in 1,000 people) 
- Depresija (često - mogu se pojaviti u manje od 1 na 10 osoba)
Day 0 
0. dan
No information is available on the effects of peginterferon beta-1a on male fertility in animals. 
Nema dostupnih podataka o učincima peginterferona beta-1a na mušku plodnost u životinja.
Starting Plegridy 
Započinjanje liječenja Plegridyjem
No gender effect on the pharmacokinetics of peginterferon beta-1a was found in a population pharmacokinetic analysis. 
Spol U populacijskoj farmakokinetičkoj analizi s peginterferonom beta-1a nije pronađen utjecaj spola na farmakokinetiku.
Instructions for injecting Plegridy pre-filled syringe 
Upute za ubrizgavanje Plegridyja u napunjenoj štrcaljki
Cytopenias, including rare severe neutropenia and thrombocytopenia, have been observed in patients treated with Plegridy. 
uključujući i rijetku tešku neutropeniju i trombocitopeniju, primijećene su u bolesnika liječenih
Injection Site 
Bilježenje injekcija
Cases of TMA, manifested as thrombotic thrombocytopenic purpura (TTP) or haemolytic uraemic syndrome (HUS), including fatal cases, have been reported with interferon beta products. 
U bolesnika koji su primali interferon beta zabilježeni su slučajevi trombotičke mikroangiopatije (TMA), manifestirani kao trombotička trombocitopenična purpura (TTP) ili hemolitičko-uremijski sindrom (HUS), uključujući i smrtne slučajeve.
Haemoglobin decreased Body temperature increased Platelet count decreased 
- svrbež kože (pruritus) - povećanje tjelesne temperature
P-value p=0.0007 
P-vrijednost p=0,0007
Giving your injection Step 5: Remove the Plegridy pen cap a. Pull the pen cap straight off and set it aside (see Figure E). 
Ravno povucite kapicu s brizgalice i odložite je sa strane (pogledajte sliku E).
Plegridy 63 mcg injection Plegridy 94 mcg injection peginterferon beta-1a SC 
Plegridy 63 μg injekcija Plegridy 94 μg injekcija peginterferon beta-1a s.c.
Only open the pack when you need a new pen. 
Otvorite pakiranje samo kada
Instructions for injecting Plegridy pre-filled pen 
Upute za ubrizgavanje Plegridyja u napunjenoj brizgalici
- If the solution is coloured, cloudy or you can see particles floating in it. 
ako je štrcaljka slomljena ako je otopina obojena, zamućena ili u njoj možete vidjeti plutajuće čestice.
Both cases resolved following discontinuation of Plegridy. 
U oba slučaja došlo je do regresije laboratorijskih abnormalnosti nakon prekida liječenja Plegridyjem.
Dose 2 
2. doza
Dose 3 
PRILOG III.
Pyrexia 
Plegridyja.
Instructions for injecting Plegridy pre-filled syringe BEFORE YOU START How to inject Plegridy 
Upute za ubrizgavanje Plegridyja u napunjenoj štrcaljki PRIJE NEGO POČNETE
b. Firmly press and hold down the pen on your injection site. 
Čvrsto pritisnite brizgalicu na mjesto za injekciju i tako je zadržite.
- Read and follow the advice given in the instructions in section 7 “Instructions for injecting 
- Prije nego što počnete, pročitajte i slijedite upute o tome kako sami sebi dati injekciju u dijelu 7
P-value p=0.0003 
P-vrijednost p=0,0003
• Close the pack and put pack back in the fridge after removing one pre-filled syringe. 
• Nakon što ste izvadili jednu napunjenu štrcaljku, zatvorite pakiranje i vratite ga u hladnjak.
The Plegridy Initiation Pack contains 1x 63 micrograms pre-filled syringe (orange labelled syringe, 1st dose) and 1x 94 micrograms pre-filled syringe (blue labelled syringe, 2nd dose) in sealed plastic trays. 
(narančasto označena brizgalica, 1. doza) i 1 napunjenu brizgalicu od 94 mikrograma (plavo označena brizgalica, 2. doza) u zatvorenom plastičnom spremniku.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Pre-Filled Pen Label 125 mcg 
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE Naljepnica na napunjenoj brizgalici od 125 μg
Dosage schedule 
Raspored doziranja
Only open the pack when you need a new syringe. 
Vam je potrebna nova štrcaljka.
Follow-up 
Praćenje
Caution should be used when administering Plegridy to patients with severe renal impairment. 
Potreban je oprez kod primjene Plegridyja u bolesnika s teškim oštećenjem funkcije bubrega.
- Seizures 
- zimica
To minimise the risk of injection site reactions patients should be instructed in the use of an aseptic injection technique. 
bolesnike treba podučiti primjeni aseptičke tehnike davanja injekcije.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Pre-Filled Syringe Label Initiation Pack 
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE Naljepnica na napunjenoj štrcaljki u pakiranju za početak liječenja
Step 7: Remove the Plegridy pen from your injection site a. After the clicking sound has stopped, lift the pen from your injection site. 
7. korak: Uklonite brizgalicu Plegridy s mjesta injekcije a.
How to store Plegridy 
Kako čuvati Plegridy
- Headache - Muscle pain (myalgia) - Pain in your joints, arms, legs or neck (arthralgia) - Chills - Fever - Feeling weak and tired (asthenia) - Redness, itching or pain around the place you have injected 
- glavobolja - bol u mišićima (mialgija) - bol u zglobovima, rukama, nogama ili vratu (artralgija)
You could get a needle injury. 
Mogli biste se ubosti.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Pre-Filled Syringe Label 125 mcg 
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE Naljepnica na napunjenoj štrcaljki od 125 μg
Plegridy 125 micrograms solution for injection in pre-filled syringe peginterferon beta-1a 
Plegridy 125 mikrograma otopina za injekciju u napunjenoj štrcaljki peginterferon beta-1a
Pharmacodynamic responses were evaluated by measuring the induction of interferon-responsive genes including those encoding 2′,5′-oligoadenylate synthetase (2′,5′-OAS), myxovirus resistance protein A (MxA), and several chemokines and cytokines, as well as neopterin (D-erythro-1, 2, 3,trihydroxypropylpterin), a product of the interferon-inducible enzyme, GTP-cyclohydrolase I. Gene induction in healthy human subjects was greater in terms of peak level and exposure (area under the effect curve) for Plegridy compared to non-pegylated interferon beta-1a (IM) when both were given at the same dose by activity (6 MIU). 
Farmakodinamički odgovori procijenjeni su mjerenjem indukcije gena koji odgovaraju na interferon, uključujući gene koji kodiraju 2′,5′-oligoadenilat sintetazu (2′,5′-OAS), miksovirus otporni protein
Annualised relapse rate Rate ratio 
N Godišnja stopa relapsa Omjer stopa 95% CI
Severe renal impairment 
- iznimna slabost
In addition to those laboratory tests normally required for monitoring patients with multiple sclerosis, complete blood and differential blood cell counts, platelet counts, and blood chemistries, including liver function tests (e.g. aspartate aminotransferase (AST), alanine aminotransaminase (ALT)), are recommended prior to initiation and at regular intervals following introduction of Plegridy therapy and then periodically thereafter in the absence of clinical symptoms. 
Osim laboratorijskih testova koji su potrebni za normalno praćenje bolesnika s multiplom sklerozom, preporučuju se kompletna krvna slika i diferencijalna krvna slika, broj trombocita i biokemijske pretrage krvi,
Plegridy 125 micrograms solution for injection in pre-filled pen peginterferon beta-1a 
Plegridy 125 mikrograma otopina za injekciju u napunjenoj brizgalici peginterferon beta-1a
(rare - may affect up to 1 in 1,000 people) If you get some or all of these symptoms: - Foamy urine - Fatigue - Swelling, particularly in the ankles and eyelids, and weight gain. 
- Oštećenje na mjestu injekcije (rijetko - mogu se pojaviti u manje od 1 na 1000 osoba) Ako Vam se pojavi bilo koji od sljedećih simptoma: - Bilo kakvo oštećenje kože popraćeno oteklinom, upalom ili curenjem tekućine oko mjesta injekcije
How to use Plegridy 
Kako primjenjivati Plegridy
4.7 Effects on ability to drive and use machines 
4.7 Utjecaj na sposobnost upravljanja vozilima i rada sa strojevima Plegridy ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
There are no data on the effects of peginferferon beta-1a on human fertility. 
Plodnost Nema podataka o učincima peginterferona beta-1a na ljudsku plodnost.
- Packs can be taken out of the fridge and then put back in a fridge more than once if you need to. - Make sure the time the syringes spend out of a fridge is no more than 30 days in total. 
- Ako je potrebno, pakiranja se mogu uzeti iz hladnjaka, a zatim staviti natrag u hladnjak više od jednog puta.
• The pen is for use under the skin only (subcutaneous). 
• Napunjena brizgalica namijenjena je ubrizgavanju lijeka samo pod kožu (supkutano).
Mean [Median] no. of new T1 hypointense lesions (range) % reduction vs placebo P-value p<0.0001 
T1 hipointenzivnih lezija (raspon) % smanjenja u usporedbi s placebom
The needle cover will extend to cover the needle and will lock (see Figure I). 
Pokrov igle potpuno će pokriti iglu te se zaključati
Elevations of alanine aminotransferase and aspartate aminotransferase (>5 times ULN), were reported in 1% and <1% of placebo-treated patients and 2% and <1% of patients treated with Plegridy respectively. 
<1% bolesnika koji su primali placebo, odnosno 2% i u <1% bolesnika liječenih Plegridyjem.
(uncommon - may affect up to 1 in 100 people) If you have a seizure or a fit 
Česte nuspojave (mogu se pojaviti u manje od 1 na 10 osoba) - mučnina ili povraćanje
Second injection: 94 micrograms, choose blue syringe 
94 mikrograma, odaberite plavu štrcaljku
These blood tests will be in addition to the tests which are normally done to monitor your MS. - The functioning of your thyroid gland will be checked regularly or whenever thought necessary by your doctor. 
Te krvne pretrage bit će dodatak pretragama koje se normalno obavljaju kako bi se pratilo Vašu multiplu sklerozu.
Mean [Median] no. of Gd-enhancing lesions (range) % reduction vs placebo P-value p<0.0001 
lezija (raspon) % smanjenja naspram placeba
Race had no effect on the pharmacokinetics of peginterferon beta-1a in a population pharmacokinetic analysis. 
Rasa U populacijskoj farmakokinetičkoj analizi s peginterferonom beta-1a nije pronađen utjecaj rase na farmakokinetiku.
Aspartate aminotransferase increased 
uključujući testove jetrene funkcije (npr. aspartat aminotransferaza (AST), alanin aminotransaminaza
Package leaflet: Information for the user Plegridy 63 micrograms solution for injection in pre-filled syringe Plegridy 94 micrograms solution for injection in pre-filled syringe Plegridy 125 micrograms solution for injection in pre-filled syringe peginterferon beta-1a 
Uputa o lijeku: Informacije za korisnika Plegridy 63 mikrograma otopina za injekciju u napunjenoj štrcaljki Plegridy 94 mikrograma otopina za injekciju u napunjenoj štrcaljki Plegridy 125 mikrograma otopina za injekciju u napunjenoj štrcaljki peginterferon beta-1a
If you get some or all of these symptoms: - Increased bruising or bleeding - Extreme weakness - Headache, dizziness or light-headedness 
Ako vam se pojavi bilo koji od sljedećih simptoma: - žutilo kože ili bjeloočnica - svrbež po cijelom tijelu - mučnina, povraćanje
Plegridy 125 micrograms solution for injection in pre-filled syringe Each pre-filled syringe contains 125 micrograms of peginterferon beta-1a* in 0.5 mL solution for injection. 
Plegridy 125 mikrograma otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 125 mikrograma peginterferona beta-1a* u 0,5 ml otopine za injekciju.
How to store Plegridy 6. 
Kako primjenjivati Plegridy 4. Moguće nuspojave
Plegridy 63 micrograms solution for injection in pre-filled syringe Plegridy 94 micrograms solution for injection in pre-filled syringe peginterferon beta-1a 
Plegridy 63 mikrograma otopina za injekciju u napunjenoj štrcaljki Plegridy 94 mikrograma otopina za injekciju u napunjenoj štrcaljki peginterferon beta-1a
Package leaflet: Information for the user Plegridy 63 micrograms solution for injection in pre-filled pen Plegridy 94 micrograms solution for injection in pre-filled pen Plegridy 125 micrograms solution for injection in pre-filled pen peginterferon beta-1a 
Uputa o lijeku: Informacije za korisnika Plegridy 63 mikrograma otopina za injekciju u napunjenoj brizgalici Plegridy 94 mikrograma otopina za injekciju u napunjenoj brizgalici Plegridy 125 mikrograma otopina za injekciju u napunjenoj brizgalici peginterferon beta-1a
• Hold the Plegridy pre-filled syringe at a 90° angle to the injection site. 
7. korak: Ubrizgajte lijek • Držite Plegridy štrcaljku pod kutom od 90° u odnosu na mjesto uboda.
Injecting yourself 
Davanje injekcije
Peginterferon beta-1a has not been tested for reproductive toxicity in pregnant animals. 
Reproduktivna toksičnost Reproduktivna toksičnost peginterferona beta-1a nije ispitana u skotnih životinja.
Plegridy 125 micrograms solution for injection in pre-filled pen Each pre-filled pen contains 125 micrograms of peginterferon beta-1a* in 0.5 mL solution for injection. 
Plegridy 125 mikrograma otopina za injekciju u napunjenoj brizgalici Jedna napunjena brizgalica sadrži 125 mikrograma peginterferona beta-1a* u 0,5 ml otopine za injekciju.
Step 6: Gently pinch the injection site 
6. korak: Nježno prstima stisnite mjesto za injekciju
- Store in the original package in order to protect from light. 
- Čuvajte Plegridy u originalnom pakiranju radi zaštite od svjetlosti.